Antibodies could be key to development of vaccines for AIDS

Researchers from Los Alamos National Laboratory, Duke University School of Medicine, Boston University, the National Institutes of Health and others collaborated on a study to see how AIDS spread through the body.  According to R&D Magazine, they found a broadly cross-reactive neutralizing antibody and  the founder virus to understand how this virus spreads through the body could be the key to determining what kind of vaccine could be developed.

Through developing an atom-by-atom picture of how the virus spread, they found:

...induces the body to create antibodies that can neutralize more than one strain of the virus is crucial to creating a vaccine that can stay ahead of the virus as it mutates in the body. The intensely focused X-rays of the APS were used to hone in on a small portion of the epitope protein in the HIV virus that is recognized by the body’s immune system and the broadly neutralizing antibody it triggers to develop

This June at the Vaccine Development and Production Summit, we look at the development and innovation you need to stay ahead of the game in the vaccine development market. Presentations from Matrivax Research and Development Corporation and CureVac GmbH will be looking at how to develop new vaccines and the innovative processes for developing them. For more information on these sessions and the rest of the program, download the agenda. If you'd like to join us at Vaccine Development and Production Summit, as a reader of this blog when you register to join us and mention code VDPS13JP, you'll save 20% off the standard rate!

Share this article with your social network, just click below to share now!

Share |